Business, energy, technology, markets and global industry news from Business News Today

Graves’ disease

PharmaDeviceNews Graves’ disease
Yarrow Bioscience’s merger with VYNE Therapeutics and the start of Phase 2 dosing for investigational YB-101 place Graves’ disease and thyroid eye disease research at the centre of the newly listed biotechnology company’s strategy. Representative image.
Pharma & Biotech

Yarrow Bioscience closes VYNE Therapeutics merger as YB-101 enters Phase 2 trial in Graves’ disease

Yarrow Bioscience starts Phase 2 dosing of YB-101 after its VYNE merger, testing a targeted approach to Graves’ disease and thyroid eye disease.

Read More
Pharma & Biotech

Viridian Therapeutics financing puts thyroid eye disease expansion strategy in sharper focus

Viridian has TED trial wins, but market entry needs capital. See why its $350m raise matters before commercialization.

Read More